Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kukje Pharma Co., Ltd. (002720:KRX), powered by AI.
Kukje Pharma Co., Ltd. is currently trading at ₩3,630. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Kukje Pharma Co., Ltd. on Alpha Lenz.
Kukje Pharma Co., Ltd.'s P/E ratio is 13.5.
“Kukje Pharma Co., Ltd. trades at a P/E of 13.5 (undervalued) with modest ROE of 6.1%. 3Y revenue CAGR of 11.5% highlights clear growth momentum.”
Ask for details →Kukje Pharma Co., Ltd. is a leading pharmaceutical company based in South Korea, primarily engaged in the research, production, and distribution of medications and medical supplies. The company's primary function is to innovate and provide accessible healthcare solutions by developing a diverse portfolio of prescription and over-the-counter drugs. Kukje Pharma serves various sectors within the pharmaceutical industry, including the development of treatments for chronic illnesses, antibiotics, and specialty medications. It plays a vital role in the healthcare market by addressing critical medical needs and contributing to the improvement of public health standards. As a dynamic entity in the global pharmaceutical industry, Kukje Pharma leverages cutting-edge research and development capabilities to maintain its competitive edge, emphasizing quality and efficacy in its offerings. The company's significant market presence enhances its ability to impact medical markets domestically in South Korea and internationally, aligning with global health trends and regulatory standards.
“Kukje Pharma Co., Ltd. trades at a P/E of 13.5 (undervalued) with modest ROE of 6.1%. 3Y revenue CAGR of 11.5% highlights clear growth momentum.”
Ask for details →Kukje Pharma Co., Ltd. (ticker: 002720) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 247 employees. Market cap is $76.8B.
The current price is ₩3,630 with a P/E ratio of 13.48x and P/B of 0.79x.
ROE is 6.09% and operating margin is 3.52%. Annual revenue is $175.5B.